Literature DB >> 35103114

Imatinib-induced retroperitoneal fibrosis in a child with chronic myeloid leukemia: a case report.

Swaminathan Keerthivasagam1, Nirmalya Roy Moulik1, Ankita Pandey1, Kunal Gala1, Vasundhara Patil1, Chetan Dhamne1, Gaurav Chatterjee1, Nikhil Patkar1, Gaurav Narula1, Shripad Banavali1.   

Abstract

A 12 year old boy with chronic myeloid leukemia (CML) presenting with bilateral pitting pedal edema and abdominal distension after about 41 months of imatinib therapy and was diagnosed to have retroperitoneal fibrosis (RPF) based on imaging and biopsy findings. He was found to have bilateral hydroureteronephrosis needing double-J stenting to the more severely affected right ureter. Imatinib was briefly interrupted and restarted later due to rising transcript levels and unavailability of other alternatives at that time which was later substituted by dasatinib once generic versions became available. Child remains asymptomatic after 18 months of DJ stenting. RPF is a rare complication of imatinib this being the second case reported in the literature. AJBR
Copyright © 2021.

Entities:  

Keywords:  Imatinib; pediatric CML; retroperitoneal fibrosis

Year:  2021        PMID: 35103114      PMCID: PMC8784644     

Source DB:  PubMed          Journal:  Am J Blood Res        ISSN: 2160-1992


  10 in total

1.  Drug-induced retroperitoneal fibrosis: short aetiopathogenetic note, from the past times of ergot-derivatives large use to currently applied bio-pharmacology.

Authors:  C Alberti
Journal:  G Chir       Date:  2015 Jul-Aug

Review 2.  Uncommon or delayed adverse events associated with imatinib treatment for chronic myeloid leukemia.

Authors:  Rishard Salie; Richard T Silver
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2010-10

Review 3.  Management of chronic myeloid leukemia in childhood.

Authors:  Meinolf Suttorp; Louise Eckardt; Josephine Tabea Tauer; Frederic Millot
Journal:  Curr Hematol Malig Rep       Date:  2012-06       Impact factor: 3.952

Review 4.  Idiopathic and secondary forms of retroperitoneal fibrosis: a diagnostic approach.

Authors:  M L Urban; A Palmisano; M Nicastro; D Corradi; C Buzio; A Vaglio
Journal:  Rev Med Interne       Date:  2014-11-18       Impact factor: 0.728

Review 5.  Idiopathic Retroperitoneal Fibrosis.

Authors:  Augusto Vaglio; Federica Maritati
Journal:  J Am Soc Nephrol       Date:  2016-02-09       Impact factor: 10.121

6.  Idiopathic retroperitoneal fibrosis: a retrospective review of clinical presentation, treatment, and outcomes.

Authors:  Tanaz A Kermani; Cynthia S Crowson; Sara J Achenbach; Harvinder S Luthra
Journal:  Mayo Clin Proc       Date:  2011-04       Impact factor: 7.616

Review 7.  Retroperitoneal fibrosis.

Authors:  Augusto Vaglio; Carlo Salvarani; Carlo Buzio
Journal:  Lancet       Date:  2006-01-21       Impact factor: 79.321

Review 8.  Presentation of idiopathic retroperitoneal fibrosis in the pediatric population.

Authors:  Oren F Miller; Loren J Smith; Elizabeth X Ferrara; Irene M McAleer; George W Kaplan
Journal:  J Pediatr Surg       Date:  2003-11       Impact factor: 2.545

9.  Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase.

Authors:  Tariq I Mughal; Andrew Schrieber
Journal:  Biologics       Date:  2010-12-02

10.  [Chronic myelogenous leukemia in children complicated with retroperitoneal fibrosis: a case report].

Authors:  Z Li; Yanli Zhang; J Zhou; H F Zhao; F K Yu; R R Gui; Y L Zu; Y P Song
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-09-14
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.